Abstract:Exosomes (EXOs) derived from tumor cells have been used to stimulate antitumor immune responses. It has been demonstrated that EXO released by tumor cells engineered to express cytokines are of enhanced stimulatory effect on CD8(+) cytotoxic T-lymphocyte (CTL) responses and antitumor immunity. J558 is a mouse myeloma cell line expressing tumor antigen P1A. In this study, we purified EXOTNF-a, EXOIL-2, and EXOIFN-gamma released by three cytokine-gene (TNF-alpha, IL-2 and IFN-gamma)-engineered J558 (J558(TNF-a), J558(IL-2) and J558(IFN-gamma)) tumor cell lines from their culture supernatants, respectively, by differential ultracentrifugation. These EXOs showed a "saucer" or round shape with a diameter between 50 and 90 nm by electron microscopy and contained EXO-associated proteins, such as LAMP-1 and AIP1, but not lysate-associated protein galectin, by Western blot analysis. EXO displayed expression of molecules (H-2K(d), CD54, and P1A) similarly to, but to a lesser extent to, J558 tumor cells. We then compared the stimulatory effect of these EXOs on P1A-specific CD8(+) CTL responses and antitumor immunity 6 days subsequent to intravenous (i.v.) EXO immunization (30 mu g/each BALB/c mouse). We demonstrated that EXOTNF-alpha immunization was able to induce more efficient P1A-specific CD8(+) T-cell response accounting for 0.62% of the total CD8(+) T-cell population, using PE-H-2K(d)/P1A peptide and FITC-CD8 staining by flow cytometric analysis then EXOIL-2 (0.31%) and EXOIFN-gamma (0.22%) immunization (P < 0.05), respectively, at day 6 after immunization. EXOIL-2 and EXOIFN-gamma vaccine (i.v. 30 mu g/each mouse) only protected 3 of 8 (38%) and 2 of 8 (25%) mice from tumor growth after subcutaneous (s.c.) challenging of immunized mice with J558 tumor cells (0.5 x 10(6) cells/each mouse), whereas EXOTNF-alpha immunization protected all 8 of 8 (100%) mice from tumor growth (P < 0.05). Taken together, we demonstrate that EXOTNF-a released by engineered J558(TNF-a) tumor cells more efficiently stimulate tumor antigen P1A-specific CD8(+) CTL responses and antitumor immunity than EXOIL-2 and EXOIFN-gamma released by engineered J558(IL-2) and J558(IFN-gamma) tumor cells. Therefore, TNF-alpha-expressing tumor cell-released EXO may represent a more effective EXO-based vaccine in the induction of antitumor immunity.

Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.

More efficient induction of antitumor T cell immunity by exosomes from CD40L gene-modified lung tumor cells.

Anti-tumor Effects of Exosomes Derived from Tumor Cells Modified by IFN-γ Gene

Membrane-bound HSP70-engineered Myeloma Cell-Derived Exosomes Stimulate More Efficient CD8(+) CTL- and NK-mediated Antitumour Immunity Than Exosomes Released from Heat-Shocked Tumour Cells Expressing Cytoplasmic HSP70.

Enhanced induction of dendritic cell maturation and HLA-A*0201-restricted CEA-specific CD8 + CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells

In vivo anti-tumor effect of tumor cell-derived exosomes combined with BCG

Tumor Cell-Derived Exosome-Targeted Dendritic Cells Stimulate Stronger CD8+ CTL Responses and Antitumor Immunities

Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.

Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells

Dendritic Cell-Derived Exosomes Stimulate Stronger Cd8(+) Ctl Responses and Antitumor Immunity Than Tumor Cell-Derived Exosomes

Dendritic Cells Recruit T Cell Exosomes Via Exosomal LFA-1 Leading to Inhibition of CD8+ CTL Responses Through Downregulation of Peptide/MHC Class I and Fas Ligand-Mediated Cytotoxicity

Co-expression of P1A35-43/β2m fusion protein and co-stimulatory molecule CD80 elicits effective anti-tumor immunity in the P815 mouse mastocytoma tumor model

Exosomal Pmhc-I Complex Targets T Cell-Based Vaccine to Directly Stimulate CTL Responses Leading to Antitumor Immunity in Transgenic FVBneuN and HLA-A2/HER2 Mice and Eradicating Trastuzumab-Resistant Tumor in Athymic Nude Mice

CD4 + T cell-released exosomes inhibit CD8 + cytotoxic T-lymphocyte responses and antitumor immunity

Novel Exosome-Targeted Cd4(+) T Cell Vaccine Counteracting Cd4(+)25(+) Regulatory T Cell-Mediated Immune Suppression and Stimulating Efficient Central Memory Cd8(+) Ctl Responses

A Novel Approach to Tumor Suppression Using Microencapsulated Engineered J558/TNF-alpha Cells.

Vaccine of Engineered Tumor Cells Secreting Stromal Cell-Derived Factor-1 Induces T-Cell Dependent Antitumor Responses

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors

Tumor Cell-associated Exosomes Robustly Elicit Anti-tumor Immune Responses through Modulating Dendritic Cell Vaccines in Lung Tumor

A Combination Of Exosomes Carrying Tsa Derived From Hla-A2-Positive Human White Buffy Coat And Polyi:C For Use As A Subcellular Antitumor Vaccination